Peter Vandenabeele Lab

Research focus

Cell death is a crucial process in development, homeostasis and (patho)physiology. In normal conditions about 100 billion cell die mostly by apoptosis. However, many diseased conditions are associated with a deregulated balance in cell death. Too much or too sensitive cell death is associated with inflammatory and degenerative diseases, while too little or too insensitive cell death is associated with development of cancer and with therapeutic resistance. This implies that depending on the particular role of cell death in a given disease therapeutic strategies could be envisioned that either sensitize or desensitize cell death pathway. However, in order to do so, a profound knowledge is required not only of cell death pathway but also on the molecular mechanism that regulate these cell death pathways.

The VIB research unit of Peter Vandenabeele focuses on the molecular mechanisms of different cell death modalities (a.o. apoptosis, necroptosis, ferroptosis, immunogenic cell death) and cellular stress (ER stress), their regulation, their functional interactions and the role herein of caspases, RIPK and other signalling molecules. The unit is both interested in cell autonomous as well as intercellular aspects of cell death and cellular stress such as communication with the innate immune system. These processes are studied in an integrated way at the level of biochemistry, cell biology, development of conditional transgenic models and their role in various diseases models such as sepsis, skin inflammation and cancer, and intestinal inflammation and cancer. In order to identify novel targets in signalling of cell death modalities we developed a cellular screening platform in which we screen customized functional classes of libraries of sh/siRNAs (kinases, ubiquitylating enzymes, etc.), libraries of known clinical drugs and series of chemical compounds. The hits are then further examined in cellular systems and in experimental disease models for their potential to modulate cell death pathways or to influence disease models.

In the Bertrand subgroup, we focus on the elucidation of the molecular mechanisms regulating stress-induced cell survival/death, as well as innate immune/inflammatory responses, with a particular interest on the role of post-translational modifications, such as phosphorylation and ubiquitylation. This group is currently characterizing the cell death checkpoints (apoptotic and necroptotic) downstream of TNFR1, as well as identifying new regulators of death induced by endoplasmic reticulum (ER) stress.

In the Declercq subgroup we mainly focus on understanding the role of RIPK1, 3 and 4 and MLKL in inflammation and cancer in the skin. Therefore we make use of cellular models and in vivo mouse models. We are especially interested in investigating whether RIPK1, RIPK3 or MLKL can serve as therapeutic targets in skin inflammation. In addition, we investigate the functions of RIPK4 and secondary modifications controlling its activity.

In the Riquet subgroup, we are interested in biosensing and visualizing in a dynamic way complex formation, proteolysis and kinase activity during different forms of cellular stress and cell death. As a proof of concept we want to reveal the dynamics of RIPK1, RIPK3, and MLKL complex formation and activation in the initiation and execution phase of necroptosis in living cells and later in vivo. The dynamics and the visualization of these processes provide us with fundamental insights in the timing and subcellular localization of these processes in different cellular conditions, and might be very useful to think about therapeutic strategies and to validate the activity of novel and existing drugs.

Our fundamental research may have prognostic, diagnostic and therapeutic applications in cancer, inflammatory and neurodegenerative diseases, and skin pathologies.
Peter Vandenabeele’s work has been published in almost 300 articles and has been cited over 23000 times, with an h index of 81, according to Web of Science. Peter Vandenabeele is holder of the prestigious Methusalem grant from the Flemish Government.
Peter Vandenabeele has been chairman of the 11th and 18th Euroconference on Apoptosis organized in Ghent 2003 and 2010 by the European Cell Death Organization (ECDO).
He co-organized the first Symposium on ‘Mechanisms of Innate Immunity, Cell Death and Inflammation’ in 2014 in Ghent and will be chair of the bi-annual international TNF meeting in 2015 in Ghent in honour of Prof. Dr. Em. Walter Fiers.


> Watch the YouTube movies about apoptosis. - ©Peter Vandenabeele Lab - Vanden Berghe et al. CDD "2010"


> video on basic research on cell death by Peter Vandenabeele - ©VIB, 2014


Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastomaHassannia B Wiernicki B Ingold I Qu F Van Herck S Tyurina Y Bayir H Abhari B Angeli J Choi S Meul E Heyninck K Declerck K Chirumamilla C Lahtela-Kakkonen M Van Camp G Krysko D Ekert P Fulda S De Geest B Conrad M Kagan V Vanden Berghe W* Vandenabeele P* Vanden Berghe T*JOURNAL OF CLINICAL INVESTIGATION, 128, 3341-3355, 2018* or °: authors contributed equally
MK2 phosphorylation of RIPK1 regulates TNF-mediated cell deathDondelinger Y Delanghe T Rojas Rivera D* Priem D* Delvaeye T Bruggeman I Van Herreweghe F Vandenabeele P Bertrand MNATURE CELL BIOLOGY, 19, 1237-1247, 2017* or °: authors contributed equally
Elevated DeltaNp63alpha Levels Facilitate Epidermal and Biliary Oncogenic TransformationDevos Michael Gilbert Barbara Denecker Geertrui Leurs Kirsten McGuire Conor Lemeire Kelly Hochepied Tino Vuylsteke M Lambert J Van Den Broecke C. Libbrecht L Haigh J Berx Geert Lippens Saskia Vandenabeele Peter Declercq WimJOURNAL OF INVESTIGATIVE DERMATOLOGY, 137, 494-505, 2017
Regulated necrosis: disease relevance and therapeutic opportunitiesConrad M* Angeli J* Vandenabeele P Stockwell BNATURE REVIEWS DRUG DISCOVERY, 15, 348-66, 2016* or °: authors contributed equally
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor ImmunityAaes T Kaczmarek A Delvaeye T De Craene B De Koker S Heyndrickx L Delrue I Taminau J Wiernicki B De Groote P Garg A Leybaert L Grooten J Bertrand M Agostinis P Berx G Declercq W Vandenabeele P* Krysko D*Cell Reports, 15, 274-287, 2016* or °: authors contributed equally

Job openings


18 of the world’s most influential researchers at VIB

20/11/2019 - Each year, Clarivate analytics identifies the world’s most influential researchers who have been cited most frequently by their peers over the last decade. No less than 18 VIB researchers are part of this highly acclaimed group of influential scientists.

Scientists shed new light on infection process of the gastrointestinal pathogen C. difficile

21/11/2018 - Scientists from the VIB-UGent Center for Inflammation Research identified mechanisms by which the bacterial pathogen Clostridium difficile kills intestinal epithelial cells (IECs), thus destroying the protective mucosal barrier of the intestinal tract

New weapon against chemotherapy-resistant cancer cells discovered

16/07/2018 - Research from VIB, Ghent University and the University of Antwerp, led by the brothers Tom and Wim Vanden Berghe, has led to the discovery of a new molecular mechanism that can kill cancer cells in mice.

Identification of a novel cell death checkpoint in the TNF signalling pathway

19/09/2017 - The research team of Prof. Bertrand (VIB-UGent), in the unit headed by Prof. Vandenabeele, is investigating the molecular mechanisms that protect the cells from death, and which are dysregulated in pathologic conditions.

New insights in cancer therapy from cell death research: Killed cancer cells serve as a potent anti-cancer vaccine

31/03/2016 - ​Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates the immune system to prevent the outgrowth of cancer cells.

A wake-up call for biomedical research on mouse models

15/12/2015 - Tom Vanden Berghe and colleagues from the Peter Vandenabeele Lab (VIB/UGent) have demonstrated how the side effects of genetic modification of mice can complicate the interpretation of biomedical research.

Unexpected role for the IKK complex in protecting cells from death

18/09/2015 - The team of Prof. Bertrand in the group of Prof. Vandenabeele, demonstrates that the IKK complex protects cells from death by inactivating RIPK1, thereby revealing an unexpected NF-kB-independent new role of the IKK complex.

Most cited article published in Cell Death & Disease is from the Peter Vandenabeele lab (VIB/UGent)

28/08/2015 - The journal Cell Death & Disease gives an overview of their most cited papers. N°1 in Europe is one from the group of Peter Vandenabeele.

Investigators at VIB and UGent have developed a tool for more accurate interpretation of biomedical research

23/07/2015 - The research group of Prof Peter Vandenabeele (VIB/UGent) recently used tangible examples to demonstrate how the side effects of genetic modification of mice can complicate the interpretation of biomedical research.

Peter Vandenabeele (VIB-UGent) receives FWO excellence prize

01/07/2015 - Every five years, FWO Flanders selects five exceptional scientists in Flanders who play an international leading role in their field and have pushed the boundaries of their field.

A thin line between cell survival and cell death

29/12/2014 - Nozomi Takahashi and Peter Vandenabeele (Inflammation Research Center, UGent) have unraveled the crucial role of RIPK1 protein in keeping our gut epithelium intact.

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

02/02/2009 - Foamix Ltd., a leading worldwide developer of topical foams for dermatology and gynecology has entered into an agreement with VIB for the development of a unique topical drug for the treatment of Psoriasis.

Caspase-14 protects our skin against UVB and dehydration

21/05/2007 - VIB researchers have demonstrated that the caspase-14 protein − whose function has been unknown up to now − not only plays a role in maintaining the balance of moisture in the skin but also offers protection against UVB rays.

Peter Vandenabeele

Peter Vandenabeele

Research area(s)

Model organism(s)


​​PhD: Ghent University, Belgium, 1990
VIB Group leader since 1996

Contact Info

VIB-UGent Center for Inflammation ResearchUGent-VIB Research Building FSVMTechnologiepark 71 9052 GENTRoute description